% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • Bio_guyo Bio_guyo Aug 24, 2012 10:08 AM Flag

    Change in fundamentals yet no change in share price

    Interesting that one of the leading competitors to Incivek dominance of the HepC market, BMY, has had their lead next-generation treatment regimen fail, and yet VRTX share price hasn't responded accordingly. It's one of those cases where the fundamentals for VRTX just improved considerably without the market acknowledging it.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
87.21+2.21(+2.60%)Sep 30 4:00 PMEDT